Featured Oncology NewsMerck, Pfizer Pull The Plug On Ovarian Cancer Trial
March 20, 2019
GSK’s Endometrial Cancer Drug To Be Filed Later This Year
March 20, 2019
J&J And Sientra Get FDA Warning Letters Over Breast Implants
March 20, 2019
California Jury Finds Roundup Caused Man's Cancer
March 20, 2019
Original articles, thought leader interviews, and other resources covering testing, patient selection and treatment options in AML.
Supported by:
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
FDA Approves First Immunotherapy Regimen For Breast Cancer
Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
Adcom Gives Karyopharm a Second Chance With Selinexor
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
[by phone or online via webcast]
[by phone or online via webcast]
Vienna, Austria
Orlando, FL
Atlanta, GA
Dubrovnik, Croatia
[by phone or online via webcast]
Orlando, FL
[by phone or online via webcast]
Portland, ME
Geneva, Switzerland
[by phone or online via webcast]
[by phone or online via webcast]
[by phone or online via webcast]
[by phone or online via webcast]
[by phone or online via webcast]
Berlin, Germany
Denver, CO
San Diego, CA
Atlanta, GA
[by phone or online via webcast]
[by phone or online via webcast]
Chicago, IL
Portland, OR
RAI Amsterdam, The Netherlands
Lugano, Switzerland
Bellevue, WA
Austin, TX
Baltimore, MD
San Diego, CA
San Diego, CA
Chicago, IL
San Francisco, CA
Barcelona, Spain
Buenos Aires, Argentina
New Orleans, LA
Scottsdale, AZ
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Roche Gets FDA Nod For Tecentriq In Small Cell Lung ...
March 19th 2019 by H. Jack West, MD
This is an important and appropriate FDA approval. Though the improvement in median overall surviva...
Read More
Death By 1,000 Clicks: Where Electronic Health Recor...
March 19th 2019 by Howard S. Hochster, MD
This amazing article should be required reading for all physicians and healthcare administrators. T...
Read More
Prophylactic Cranial Irradiation Improves Disease-Fr...
March 19th 2019 by Howard Sandler, MD, MS, FASTRO
Prophylactic cranial irradiation (PCI) is generally offered to patients with limited small cell lun...
Read More
Testosterone Slows Prostate Cancer Recurrence In Low...
March 18th 2019 by Tomasz M. Beer, MD, FACP
This is an interesting and complex finding. First it demonstrates that the relationship between te...
Read More
AMA Says Prior Authorizations Increasing, Interferin...
March 14th 2019 by William McGivney, PhD
Payer Prior Authorization: Intrusion, Disruption and Patient Harm Is it any surprise that the fre...
Read More
FDA Approves Pfizer's Trastuzumab Biosimilar, Trazim...
March 12th 2019 by Debu Tripathy, MD
We will be seeing many more biosimilars approved in the coming years. This term is applied to biol...
Read More
OBR Green